Spero Therapeutics, Inc.
SPRO
$2.33
$0.010.43%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -61.65% | 141.56% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -61.65% | 141.56% | |||
| Cost of Revenue | -19.44% | -21.56% | |||
| Gross Profit | -189.71% | 145.49% | |||
| SG&A Expenses | -28.99% | -13.86% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -22.83% | -18.99% | |||
| Operating Income | -210.42% | 83.78% | |||
| Income Before Tax | -334.24% | 87.74% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -334.24% | 87.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -334.24% | 87.74% | |||
| EBIT | -210.42% | 83.78% | |||
| EBITDA | -210.46% | 83.78% | |||
| EPS Basic | -333.00% | 87.90% | |||
| Normalized Basic EPS | -319.44% | 88.35% | |||
| EPS Diluted | -333.00% | 87.90% | |||
| Normalized Diluted EPS | -319.44% | 88.35% | |||
| Average Basic Shares Outstanding | 0.45% | 1.17% | |||
| Average Diluted Shares Outstanding | 0.45% | 1.17% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||